Amendment to the Claims

1-33.   (canceled)

34.   (previously presented) A composition comprising a CD20 binding molecule, wherein

the CD20 binding molecule comprises:

    a) a light chain variable region, wherein the light chain variable region comprises:

        i) a CDRL1 amino acid sequence selected from the group consisting of SEQ ID

NO:1, SEQ ID NO:3, and SEQ ID NO:5;

        ii) a CDRL2 amino acid sequence selected from the group consisting of SEQ ID

NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13;

        iii) a CDRL3 amino acid sequence selected from the group consisting of SEQ ID

NO:17, SEQ ID NO:19, and SEQ ID NO:21;

        iv) an FRL1 amino acid sequence consisting of SEQ ID NO:71;

         v) an FRL2 amino acid sequence consisting of SEQ ID NO:72;

        vi) an FRL3 amino acid sequence consisting of SEQ ID NO:73; and

        vii) an FRL4 amino acid sequence consisting of SEQ ID NO:74.

    b) a heavy chain variable region, wherein the heavy chain variable region comprises:

        i) a CDRH1 amino acid sequence selected from the group consisting of SEQ ID

NO:23 and SEQ ID NO:25;

        ii) a CDRH2 amino acid sequence selected from the group consisting of SEQ ID

NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37,

and SEQ ID NO:39;

        iii) a CDRH3 amino acid sequence selected from the group consisting of SEQ ID

NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53,

SEQ ID NO:55, and SEQ ID NO:57;

iv) an FRH1 amino acid sequence consisting of SEQ ID NO:79;

v) an FRH2 amino acid sequence consisting of SEQ ID NO:80;

vi) an FRH3 amino acid sequence consisting of SEQ ID NO:81; and

vii) an FRH4 amino acid sequence consisting of SEQ ID NO:82.

35.   (previously presented) The composition of Claim 34, wherein the CD20 binding molecule comprises the AME 33 Fab.

36.   (previously presented) The composition of Claim 34, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (koff) for human CD20 of 5.0×10^{-4} s^{-1} or less.

37.   (previously presented) The composition of Claim 36, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.

38.   (previously presented) The composition of Claim 36, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of 2.5×10^{-4} s^{-1} or less.

39.   (previously presented) The composition of Claim 36, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of 5.0×10^{-5} M^{-1} s^{-1} or greater.

40.   (previously presented) A method of treating B cell lymphoma comprising administering to a subject a composition comprising a CD20 binding molecule, wherein the CD20 binding molecule comprises:

a) a light chain variable region, wherein the light chain variable region comprises:

i) a CDRL1 amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, and SEQ ID NO:5;

ii) a CDRL2 amino acid sequence selected from the group consisting of SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:11, and SEQ ID NO:13;

iii) a CDRL3 amino acid sequence selected from the group consisting of SEQ ID NO:17, SEQ ID NO:19, and SEQ ID NO:21;

iv) an FRL1 amino acid sequence consisting of SEQ ID NO:71; v) an FRL2 amino acid sequence consisting of SEQ ID NO:72;

vi) an FRL3 amino acid sequence consisting of SEQ ID NO:73; and

vii) an FRL4 amino acid sequence consisting of SEQ ID NO:74.

b) a heavy chain variable region, wherein the heavy chain variable region comprises:

i) a CDRH1 amino acid sequence selected from the group consisting of SEQ ID NO:23 and SEQ ID NO:25;

ii) a CDRH2 amino acid sequence selected from the group consisting of SEQ ID NO:27, SEQ ID NO:29, SEQ ID NO:31, SEQ ID NO:33, SEQ ID NO:35, SEQ ID NO:37, and SEQ ID NO:39;

iii) a CDRH3 amino acid sequence selected from the group consisting of SEQ ID NO:43, SEQ ID NO:45, SEQ ID NO:47, SEQ ID NO:49, SEQ ID NO:51, SEQ ID NO:53, SEQ ID NO:55, and SEQ ID NO:57;

iv) an FRH1 amino acid sequence consisting of SEQ ID NO:79;

v) an FRH2 amino acid sequence consisting of SEQ ID NO:80;

vi) an FRH3 amino acid sequence consisting of SEQ ID NO:81; and

vii) an FRH4 amino acid sequence consisting of SEQ ID NO:82.

41.   (previously presented) The method of Claim 40, wherein the CD20 binding molecule comprises the AME 33 Fab.

42.   (previously presented) The method of Claim 40, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 5.0×10^{-10} M or less, and a dissociation rate (koff) for human CD20 of 5.0×10^{-4} s^{-1} or less.

43.   (previously presented) The method of Claim 42, wherein the CD20 binding molecule has a binding affinity (K_d) for human CD20 of 1.5×10^{-10} M or less.

44.   (previously presented) The method of Claim 42, wherein the CD20 binding molecule has a dissociation rate (k_{off}) for human CD20 of 2.5×10^{-4} s^{-1} or less.

45.   (previously presented) The method of Claim 42, wherein the CD20 binding molecule has an association rate (k_{on}) for human CD20 of 5.0×10^{-5} M^{-1} s^{-1} or greater.

46.   (previously presented) The method of Claim 40, wherein the B cell lymphoma is Non-Hodgkin's lymphoma.

47.   (previously presented) The method of Claim 46, wherein the Non-Hodgkin's lymphoma is Waldenstrom's macroglobulinemia.

48.   (new) A composition of Claim 34, wherein the light chain variable region comprises an amino acid sequence of SEQ ID NO:59 and the heavy chain variable region comprises an amino acid sequence of SEQ ID NO:61.